Combination therapy using immunoglobulin and C1-Inhibitor
AssigneesCSL Behring GmbH, The Government of the United States of America
InventorsMilan Basta, Xinzhi Chen, Mark Mattson
Life of this patent
Estimating the term…
Abstract
Methods are disclosed for treating cerebral ischemia using a combination of C1-INH and immunoglobulin, such as human plasma derived immunoglobulin (IVIG).
Claims17
A method of treating or reducing the effects of inflammation damage or reperfusion injury following cerebral ischemia, comprising administering to a patient in need thereof a composition comprising human plasma derived immunoglobulin G as intravenous immunoglobulin G (IVIG) or subcutaneous immunoglobulin G (SCIG), and a composition comprising C1-Inhibitor (C1-INH), wherein the IVIG is administered at a dose from 0.05 g/kg to 0.5 g/kg of bodyweight, and the C1-INH is administered at a dose of approximately 75 U/kg of bodyweight.
Dependencies are inferred from the claim text.